Semaglutide is a GLP-1 receptor agonist originally approved for managing Type 2 diabetes
Appetite suppression, reduced cravings, and steady metabolic support, especially when paired with a healthy diet and lifestyle
Our non-surgical treatment options are designed to reduce pain, restore mobility, and support long-term recovery without lengthy downtime
A typical semaglutide-associated increase of 2 to 4 BPM is not usually felt and is unlikely to be dangerous for healthy adults
Taking doses closer than the recommended 2-day minimum interval could theoretically increase drug exposure beyond intended levels, potentially intensifying these gastrointestinal symptoms
The booming online market for GLP-1s is giving people cheaper access to weight-loss drugs, but often without regulation or medical guidance